DNMT3B and breast carcinoma: DNMT3B gene amplification was observed in breast cancer cells and was associated with resistance to DNA demethylating drugs, including Decitabine, 5-azacytidine (Vidaza), and SGI-1027 (Simo-Riudalbas et al., 2011).